BCKDK Deficiency

1. Disease Information

1.1 Concise overview

BCKDK deficiency is a rare, autosomal recessive neuro-metabolic disorder caused by biallelic loss-of-function variants in BCKDK, the mitochondrial kinase that normally phosphorylates and inhibits the branched-chain α-ketoacid dehydrogenase (BCKDH) complex. Loss of BCKDK removes this inhibitory brake, increasing BCKDH activity and leading to excessive catabolism of leucine, isoleucine, and valine, with low plasma and cerebrospinal fluid (CSF) BCAA concentrations and a neurodevelopmental phenotype characterized by autism spectrum disorder (ASD), intellectual disability/developmental delay, seizures/epileptic encephalopathy, and microcephaly. (novarino2012mutationsinbckdkinase pages 1-2, boemer2022novellossof pages 1-2)

The initial report explicitly framed the condition as a “potentially treatable form of autism with epilepsy” through dietary BCAA repletion, based on human genetics plus rescue in a Bckdk−/− mouse model. (novarino2012mutationsinbckdkinase pages 5-8)

1.2 Key identifiers

The retrieved full-text sources in this run did not explicitly provide OMIM, Orphanet (ORPHA), ICD-10/ICD-11, MeSH, or MONDO identifiers for BCKDK deficiency; therefore, these identifiers cannot be responsibly asserted from the evidence available here. (singh2024computationalstructuralgenomics pages 12-12)

1.3 Synonyms and alternative names (from retrieved literature)

• Branched-chain ketoacid dehydrogenase kinase deficiency / BCKDK deficiency (babazade2026revealingbckdkdeficiency pages 1-2)
• BCKD-kinase deficiency (terminology used in the original Science paper title and text) (novarino2012mutationsinbckdkinase pages 5-8)
• Descriptive framing in the initial report: treatable autism with epilepsy (novarino2012mutationsinbckdkinase pages 5-8)

1.4 Evidence source types

The disease understanding in this report is derived primarily from: - Aggregated disease-level evidence from case series and mechanistic human studies (Science 2012; IJMS 2022) (novarino2012mutationsinbckdkinase pages 5-8, boemer2022novellossof pages 2-6) - Model organism evidence (mouse Bckdk−/−; spontaneous rat model) used to test causal mechanisms and interventions (novarino2012mutationsinbckdkinase pages 5-8, zigler2016aspontaneousmissense pages 2-5)

2. Etiology

2.1 Disease causal factors

• Genetic cause (primary): biallelic pathogenic variants in BCKDK (loss-of-function), segregating recessively in consanguineous families and sibling sets. (novarino2012mutationsinbckdkinase pages 1-2, boemer2022novellossof pages 2-6)
• Mechanistic cause: loss of BCKDK-mediated inhibitory phosphorylation of BCKDH E1α leads to increased BCAA catabolic flux and low systemic/CSF BCAAs. (novarino2012mutationsinbckdkinase pages 5-8, zigler2016aspontaneousmissense pages 2-5)

2.2 Risk factors

• Family history/consanguinity: initial families were consanguineous with recessive segregation, indicating increased risk in consanguineous unions. (novarino2012mutationsinbckdkinase pages 1-2)

No environmental, infectious, or lifestyle risk factors were identified in the retrieved texts as primary causes.

2.3 Protective factors

No genetic or environmental protective factors were described in the retrieved texts.

2.4 Gene–environment interactions

No explicit gene–environment interactions were described in the retrieved texts for BCKDK deficiency.

3. Phenotypes

3.1 Core phenotype spectrum (human)

Across the initial discovery cohort and subsequent reports, core features include: - Neurodevelopmental impairment: developmental delay/intellectual disability with severe language impairment/absent speech. (boemer2022novellossof pages 2-6, babazade2026revealingbckdkdeficiency pages 1-2) - ASD/autistic features: prominent in the initial description and reiterated in later case reports. (novarino2012mutationsinbckdkinase pages 5-8, babazade2026revealingbckdkdeficiency pages 3-5) - Epilepsy / epileptic encephalopathy: early generalized seizures and epileptic encephalopathy in some cases; seizure control can improve with dietary therapy in some reports. (boemer2022novellossof pages 2-6, boemer2022novellossof pages 6-8) - Microcephaly (often progressive/postnatal): repeatedly reported. (boemer2022novellossof pages 2-6, babazade2026revealingbckdkdeficiency pages 3-5)

Frequency data (limited): One literature-review excerpt reports very high frequencies for several features in published cohorts (e.g., global developmental delay and microcephaly reported in most individuals in that summarized cohort), but the underlying cohort composition is not fully verifiable from the excerpt alone; thus, frequencies should be treated cautiously. (babazade2026revealingbckdkdeficiency pages 3-5)

3.2 Age of onset and course

• Onset is typically infancy/early childhood, with psychomotor delay from the first year reported in a sibling series; regression in the second year occurred in 2/3 siblings in that report. (boemer2022novellossof pages 2-6)
• The disorder is generally chronic/lifelong, with potential partial responsiveness to nutritional therapy and likely better outcomes with earlier initiation. (babazade2026revealingbckdkdeficiency pages 3-5, boemer2022novellossof pages 6-8)

3.3 Laboratory phenotype

A hallmark is persistently low BCAA concentrations: - In a sibling series, CSF BCAA concentrations were markedly reduced relative to reference ranges (e.g., CSF leucine values such as 29 and 15 vs reference 74–203; CSF isoleucine values such as 13 and 7 vs reference 42–124; CSF valine values such as 62 and 44 vs reference 145–337). (boemer2022novellossof pages 6-8)

3.4 Suggested HPO terms

A structured phenotype-to-ontology mapping is provided in Artifact 01.

Table: This table maps the main reported clinical and mechanistic features of BCKDK deficiency to suggested ontology terms for phenotype, process, cell type, and anatomy. It is useful for structuring disease-knowledge-base annotations while staying close to the available evidence.

4. Genetic / Molecular Information

4.1 Causal gene

• BCKDK (branched-chain ketoacid dehydrogenase kinase). (novarino2012mutationsinbckdkinase pages 1-2)

4.2 Pathogenic variants reported in retrieved evidence

Human variants (examples explicitly reported): - p.M74fs, p.Arg156, p.Arg224Pro (initial pedigrees). (novarino2012mutationsinbckdkinase pages 5-8) - c.999_1001delCAC (p.Thr334del)* in 3 siblings; shown by functional assays to reduce phosphorylation of the BCKDH E1α substrate. (boemer2022novellossof pages 2-6)

Model organism variant: - Rat Bckdk G369E (homozygous) associated with loss of Ser293 phosphorylation and low plasma BCAAs. (zigler2016aspontaneousmissense pages 2-5)

4.3 Functional consequence

• Predominant mechanism is loss of kinase function (reduced inhibitory phosphorylation of BCKDH), causing increased catabolic flux and BCAA depletion. (novarino2012mutationsinbckdkinase pages 5-8, boemer2022novellossof pages 2-6)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No modifier genes, epigenetic signatures, or recurrent chromosomal abnormalities were described in the retrieved texts.

5. Environmental Information

No specific environmental toxins, lifestyle factors, or infectious triggers were reported in the retrieved texts as causal or modifying factors for BCKDK deficiency.

6. Mechanism / Pathophysiology

6.1 Core biochemical pathway and causal chain

1. Trigger: biallelic loss-of-function variants in BCKDK. (novarino2012mutationsinbckdkinase pages 1-2, boemer2022novellossof pages 2-6)
2. Molecular defect: reduced inhibitory phosphorylation of the BCKDH complex E1α subunit (loss of phospho-E1α signal in patient-derived cells; impaired phosphorylation in functional assays). (novarino2012mutationsinbckdkinase pages 5-8, boemer2022novellossof pages 2-6)
3. Metabolic consequence: increased BCAA catabolism → low plasma and CSF BCAA concentrations; newborn dried blood spots can also show low BCAA-related markers (e.g., Xle and valine). (boemer2022novellossof pages 2-6)
4. Clinical manifestation: neurodevelopmental disorder with ASD/ID/developmental delay, epilepsy/seizures, and microcephaly. (novarino2012mutationsinbckdkinase pages 5-8, boemer2022novellossof pages 2-6)

6.2 Expanded metabolomic disturbance (recent evidence)

A 2024 mouse-model study challenged a simplistic “only BCAA deficiency” model and reported broader metabolic imbalances in Bckdk−/− mice, including acylcarnitine and TCA-cycle intermediate alterations, and argued that altered flux through the pathway may be central. (ohl2024partialsuppressionof pages 9-11, ohl2024partialsuppressionof pages 1-2)

6.3 CNS access limitation as a mechanistic constraint on therapy

The 2024 mouse-model study also highlighted that enteral BCAA supplementation may raise systemic levels without restoring CSF/brain BCAA levels, consistent with constraints at the blood–brain barrier (BBB) and rapid post-dose disposal, complicating therapeutic strategy. (ohl2024partialsuppressionof pages 9-11, boemer2022novellossof pages 2-6)

6.4 Suggested ontology terms (GO/CL/UBERON/CHEBI)

• Candidate GO BP/CC, CL, and UBERON suggestions aligned to evidence are summarized in Artifact 01. (bo2024primaryrolesof pages 13-15, ohl2024partialsuppressionof pages 9-11)
• Key chemicals: leucine, isoleucine, valine (BCAAs). (boemer2022novellossof pages 6-8)

7. Anatomical Structures Affected

7.1 Organ/system level

• Nervous system (primary): neurodevelopmental phenotype implicating the brain/CNS as the primary affected system. (boemer2022novellossof pages 2-6, novarino2012mutationsinbckdkinase pages 5-8)
• Peripheral nervous system involvement: supported by a spontaneous rat model affecting both central and peripheral nervous systems. (zigler2016aspontaneousmissense pages 2-5)

7.2 Tissue/cell level

• Evidence supports a key role for neurons, including neuron-enriched BCKDK expression and cortical neuron involvement in mouse studies (cortex neuron–restricted deficiency causing neurological abnormalities). (bo2024primaryrolesof pages 13-15)

7.3 Subcellular level

• Mitochondrial compartment involvement is inherent to BCKDH regulation and BCKDK function; patient-derived cells in the 2024 discussion are described as showing mitochondrial defects. (ohl2024partialsuppressionof pages 1-2)

8. Temporal Development

• Onset: typically infancy/early childhood with early developmental delay and early seizures in severe presentations. (boemer2022novellossof pages 2-6)
• Progression: can include progressive/postnatal microcephaly and developmental regression in some cases. (boemer2022novellossof pages 2-6)
• Critical period: the literature review excerpt supports that earlier treatment (before age ~2 years) may be associated with better neurodevelopmental outcomes than later treatment. (babazade2026revealingbckdkdeficiency pages 3-5)

9. Inheritance and Population

9.1 Inheritance

• Autosomal recessive inheritance is supported by homozygous variants in affected individuals with heterozygous carrier parents (including consanguineous families). (novarino2012mutationsinbckdkinase pages 1-2, boemer2022novellossof pages 1-2)

9.2 Epidemiology

The retrieved full-text evidence in this run did not provide prevalence/incidence estimates. The condition is repeatedly described as very rare, with early reports comprising a small number of families/siblings. (boemer2022novellossof pages 6-8, novarino2012mutationsinbckdkinase pages 1-2)

10. Diagnostics

10.1 Clinical suspicion

Consider BCKDK deficiency in children with combinations of: - ASD/autistic features, global developmental delay/intellectual disability - seizures/epileptic encephalopathy - postnatal/progressive microcephaly especially in contexts of consanguinity or affected siblings. (novarino2012mutationsinbckdkinase pages 1-2, boemer2022novellossof pages 2-6)

10.2 Biochemical testing

• Plasma BCAAs: low leucine, isoleucine, valine are typical. (novarino2012mutationsinbckdkinase pages 1-2)
• CSF BCAAs: may be markedly reduced with explicit reference ranges reported in one sibling series (e.g., CSF leucine reference 74–203; isoleucine 42–124; valine 145–337). (boemer2022novellossof pages 6-8)
• Newborn dried blood spot (DBS): low BCAA-related values can be present, e.g., Xle 84 µmol/L and valine 47 µmol/L in one patient’s newborn screen; similar low values were reported for siblings. (boemer2022novellossof pages 2-6)

10.3 Genetic testing

• Whole-exome sequencing (WES) has been used to identify homozygous loss-of-function BCKDK variants in affected families, with segregation confirmation by Sanger sequencing. (boemer2022novellossof pages 8-10, novarino2012mutationsinbckdkinase pages 1-2)

10.4 Screening / early detection

• A key practical point is that newborn screening programs may detect BCKDK deficiency if low BCAA values are actively flagged, because low BCAA values can otherwise be overlooked. (boemer2022novellossof pages 8-10, boemer2022novellossof pages 6-8)

10.5 Differential diagnosis (from mechanistic context)

The initial report contrasts BCKDK deficiency (low BCAAs from increased catabolism) with maple syrup urine disease (MSUD) (high BCAAs/toxic accumulation due to defects in BCKDH complex components). This biochemical directionality (low vs high BCAAs) is a key differentiator. (novarino2012mutationsinbckdkinase pages 1-2)

11. Outcome / Prognosis

11.1 Untreated course

The retrieved evidence supports significant neurodevelopmental morbidity (ASD/ID, seizures, microcephaly) and developmental regression in some individuals. (boemer2022novellossof pages 2-6, novarino2012mutationsinbckdkinase pages 5-8)

11.2 Treatment-modified outcomes

• In a 3-sibling series, dietary therapy was associated with substantial seizure improvement and reduced hospital admissions (e.g., one child: 10 admissions in the year pre-treatment vs 1 admission during 18 months on therapy). (boemer2022novellossof pages 6-8)
• Reported developmental/behavioral improvements were more variable and less robust than seizure outcomes. (boemer2022novellossof pages 6-8)

No survival curves, mortality rates, or formal quality-of-life instruments were reported in the retrieved texts.

12. Treatment

12.1 Disease-directed nutritional therapy (current real-world implementation)

High-protein diet plus oral BCAA supplementation (leucine, isoleucine, valine) is the main disease-directed intervention reported. - In a sibling series, protein intake of ~2.5–3 g/kg/day plus BCAA supplementation was titrated; initial doses ~85–125 mg/kg/day each were insufficient, while ~135–195 mg/kg/day each given in divided doses (six times daily) achieved physiological plasma levels. (boemer2022novellossof pages 2-6) - Practical monitoring constraints include rapid post-dose disposal and dependence of measured plasma concentrations on sampling timing; frequent dosing (≥6/day) may be needed. (boemer2022novellossof pages 6-8)

MAXO suggestions (treatment actions): - Dietary supplementation (BCAA supplementation) - High-protein diet therapy - Therapeutic drug monitoring–like biochemical monitoring of plasma amino acids (as an action, not a drug) (boemer2022novellossof pages 6-8, boemer2022novellossof pages 2-6)

12.2 Evidence strength and expert-leaning interpretation

• The original discovery study provided foundational evidence of potential treatability, supported by dietary rescue experiments in Bckdk−/− mice. (novarino2012mutationsinbckdkinase pages 5-8)
• A 2024 mouse-model study provides an important caution: enteral BCAA supplementation in Bckdk−/− mice “exacerbated neurodevelopmental deficits” and did not correct key biochemical abnormalities, suggesting that simple BCAA repletion may not address the core metabolic flux disturbance and/or CNS delivery constraints. (ohl2024partialsuppressionof pages 1-2)
• The same 2024 study proposed an alternative strategy: partial suppression of downstream BCAA catabolism via Dbt haploinsufficiency partially rescued biochemical and behavioral phenotypes in mice. (ohl2024partialsuppressionof pages 9-11)

12.3 Recent developments (2023–2024) relevant to therapy landscape

• 2024 (preclinical, disease-specific): partial suppression of BCAA catabolism as a potential therapy (mouse genetic approach), and the finding that enteral supplementation may be harmful in the model. (ohl2024partialsuppressionof pages 9-11, ohl2024partialsuppressionof pages 1-2)
• 2023 (therapeutics in related contexts): potent small-molecule BCKDK inhibitors (e.g., PF-07208254) were developed for cardiometabolic indications and show that BCKDK activity is druggable; however, such inhibitors would be expected to increase BCAA catabolic flux and thus are conceptually opposite to what would be desired for BCKDK deficiency. (flach2023smallmoleculebranchedchain pages 1-2)

12.4 Clinical trials

No interventional clinical trials specifically targeting BCKDK deficiency were identified in the retrieved trial records in this run. Two observational studies retrieved are broad genomic/newborn screening or autism genetics registries rather than BCKDK-deficiency therapeutic trials: - Baby Detect: Genomic Newborn Screening (NCT05687474; observational). (trial record retrieved; see tool output) - Simons Searchlight (NCT01238250; observational autism genetics). (trial record retrieved; see tool output)

13. Prevention

Given autosomal recessive inheritance, prevention focuses on: - Genetic counseling and recurrence risk assessment for carrier parents (supported by segregation in families with heterozygous carriers). (boemer2022novellossof pages 1-2) - Carrier testing for at-risk relatives and cascade testing. - Prenatal or preimplantation genetic testing is logically applicable when the familial pathogenic variant is known; however, specific protocols were not detailed in the retrieved texts. - Secondary prevention / early detection: newborn screening strategies that include thresholds for low BCAA values could enable earlier diagnosis and earlier dietary therapy. (boemer2022novellossof pages 8-10)

14. Other Species / Natural Disease

• A spontaneous rat model (“frogleg”) with homozygous Bckdk G369E shows CNS and PNS involvement and low BCAAs, representing a naturally occurring disease model. (zigler2016aspontaneousmissense pages 2-5)

15. Model Organisms

15.1 Mouse models

• Bckdk−/− knockout mouse: shows altered brain amino acids and neurological phenotypes (hindlimb clasping, seizures) and was used for dietary rescue experiments with BCAA-enriched diets in early work. (novarino2012mutationsinbckdkinase pages 5-8)
• Bckdk−/− mouse (2024 metabolomic/therapeutic interrogation): used to test supplementation versus pathway-flux modification; enteral BCAA supplementation worsened neurodevelopmental outcomes, while Dbt haploinsufficiency partially rescued phenotypes. (ohl2024partialsuppressionof pages 1-2, ohl2024partialsuppressionof pages 9-11)

15.2 Rat models

• Spontaneous Bckdk G369E rat model with biochemical and neurologic phenotypes affecting CNS and PNS. (zigler2016aspontaneousmissense pages 2-5)

Key statistics and data points (from retrieved studies)

• Initial human genetic discovery: 3 consanguineous pedigrees with 2 affected individuals each (6 affected). (novarino2012mutationsinbckdkinase pages 5-8)
• Newborn screening biochemical examples: Xle as low as 84 µmol/L and valine 47 µmol/L on dried blood spot in one affected child. (boemer2022novellossof pages 2-6)
• CSF BCAA reference ranges used in one report: leucine 74–203, isoleucine 42–124, valine 145–337 (µmol/L). (boemer2022novellossof pages 6-8)
• Treatment intensity/implementation: in one sibling series, achieving physiologic plasma BCAA required dosing ~135–195 mg/kg/day each BCAA divided into ≥6 doses/day, with protein intake 2.5–3 g/kg/day. (boemer2022novellossof pages 2-6)
• Outcome proxy: one treated child had 10 hospital admissions in the year before therapy vs 1 admission during 18 months on therapy. (boemer2022novellossof pages 6-8)

Summary table of core findings

A cross-domain structured summary is provided below.

Table: This table summarizes core disease characteristics of BCKDK deficiency across human cases and animal models, including inheritance, phenotype, biochemical signature, variants, and treatment evidence. It also highlights the important 2024 preclinical finding that enteral BCAA supplementation may not fully correct brain disease and can worsen some mouse outcomes.

Limitations of this evidence package

• Formal disease identifiers (OMIM/Orphanet/ICD/MeSH/MONDO) were not present in the retrieved full-text sources for this run; this report therefore cannot cite them.
• A key 2023 Brain paper on newborn-screening amenability (doi:10.1093/brain/awad010) was listed as unobtainable by the search tool in this run and thus cannot be cited directly here.
• Published human treatment evidence remains based on small numbers of families/siblings; interpretation should account for phenotype variability, timing of treatment initiation, and challenges of CNS repletion demonstrated in animal models. (boemer2022novellossof pages 6-8, ohl2024partialsuppressionof pages 1-2)

References

1. (novarino2012mutationsinbckdkinase pages 1-2): Gaia Novarino, Paul El-Fishawy, Hulya Kayserili, Nagwa A. Meguid, Eric M. Scott, Jana Schroth, Jennifer L. Silhavy, Majdi Kara, Rehab O. Khalil, Tawfeg Ben-Omran, A. Gulhan Ercan-Sencicek, Adel F. Hashish, Stephan J. Sanders, Abha R. Gupta, Hebatalla S. Hashem, Dietrich Matern, Stacey Gabriel, Larry Sweetman, Yasmeen Rahimi, Robert A. Harris, Matthew W. State, and Joseph G. Gleeson. Mutations in bckd-kinase lead to a potentially treatable form of autism with epilepsy. Science, 338:394-397, Oct 2012. URL: https://doi.org/10.1126/science.1224631, doi:10.1126/science.1224631. This article has 386 citations and is from a highest quality peer-reviewed journal.

2. (boemer2022novellossof pages 1-2): François Boemer, Claire Josse, Géraldine Luis, Emmanuel Di Valentin, Jérôme Thiry, Christophe Cello, Jean-Hubert Caberg, Caroline Dadoumont, Julie Harvengt, Aimé Lumaka, Vincent Bours, and François-Guillaume Debray. Novel loss of function variant in bckdk causes a treatable developmental and epileptic encephalopathy. International Journal of Molecular Sciences, 23:2253, Feb 2022. URL: https://doi.org/10.3390/ijms23042253, doi:10.3390/ijms23042253. This article has 14 citations.

3. (novarino2012mutationsinbckdkinase pages 5-8): Gaia Novarino, Paul El-Fishawy, Hulya Kayserili, Nagwa A. Meguid, Eric M. Scott, Jana Schroth, Jennifer L. Silhavy, Majdi Kara, Rehab O. Khalil, Tawfeg Ben-Omran, A. Gulhan Ercan-Sencicek, Adel F. Hashish, Stephan J. Sanders, Abha R. Gupta, Hebatalla S. Hashem, Dietrich Matern, Stacey Gabriel, Larry Sweetman, Yasmeen Rahimi, Robert A. Harris, Matthew W. State, and Joseph G. Gleeson. Mutations in bckd-kinase lead to a potentially treatable form of autism with epilepsy. Science, 338:394-397, Oct 2012. URL: https://doi.org/10.1126/science.1224631, doi:10.1126/science.1224631. This article has 386 citations and is from a highest quality peer-reviewed journal.

4. (singh2024computationalstructuralgenomics pages 12-12): Emily Singh, Young‐In Chi, Jessica Kopesky, Michael Zimmerman, Raul Urrutia, Donald Basel, and Jessica Scott Schwoerer. Computational structural genomics and clinical evidence suggest bckdk gain‐of‐function may cause a potentially asymptomatic maple syrup urine disease phenotype. JIMD Reports, 65:144-155, Apr 2024. URL: https://doi.org/10.1002/jmd2.12419, doi:10.1002/jmd2.12419. This article has 2 citations and is from a peer-reviewed journal.

5. (babazade2026revealingbckdkdeficiency pages 1-2): Hanım Babazade, Başak Günal, Kağan Çalişgan, Esma Uygur, Gizem Durcan, Hüseyin Kılıç, Tanyel Zubarioglu, Mehmet Şerif Cansever, Çiğdem Aktuğlu-Zeybek, and Ertuğrul Kiykim. Revealing bckdk deficiency under autism: a case report, therapeutic outcomes, and literature review. Turkish Archives of Pediatrics, Dec 2026. URL: https://doi.org/10.5152/turkarchpediatr.2025.25325, doi:10.5152/turkarchpediatr.2025.25325. This article has 0 citations.

6. (boemer2022novellossof pages 2-6): François Boemer, Claire Josse, Géraldine Luis, Emmanuel Di Valentin, Jérôme Thiry, Christophe Cello, Jean-Hubert Caberg, Caroline Dadoumont, Julie Harvengt, Aimé Lumaka, Vincent Bours, and François-Guillaume Debray. Novel loss of function variant in bckdk causes a treatable developmental and epileptic encephalopathy. International Journal of Molecular Sciences, 23:2253, Feb 2022. URL: https://doi.org/10.3390/ijms23042253, doi:10.3390/ijms23042253. This article has 14 citations.

7. (zigler2016aspontaneousmissense pages 2-5): J. Samuel Zigler, Colin A. Hodgkinson, Megan Wright, Andrew Klise, Olof Sundin, Karl W. Broman, Fielding Hejtmancik, Hao Huang, Bonnie Patek, Yuri Sergeev, Stacey Hose, Cory Brayton, Jiao Xaiodong, David Vasquez, Nicholas Maragakis, Susumu Mori, David Goldman, Ahmet Hoke, and Debasish Sinha. A spontaneous missense mutation in branched chain keto acid dehydrogenase kinase in the rat affects both the central and peripheral nervous systems. PLOS ONE, 11:e0160447, Jul 2016. URL: https://doi.org/10.1371/journal.pone.0160447, doi:10.1371/journal.pone.0160447. This article has 21 citations and is from a peer-reviewed journal.

8. (babazade2026revealingbckdkdeficiency pages 3-5): Hanım Babazade, Başak Günal, Kağan Çalişgan, Esma Uygur, Gizem Durcan, Hüseyin Kılıç, Tanyel Zubarioglu, Mehmet Şerif Cansever, Çiğdem Aktuğlu-Zeybek, and Ertuğrul Kiykim. Revealing bckdk deficiency under autism: a case report, therapeutic outcomes, and literature review. Turkish Archives of Pediatrics, Dec 2026. URL: https://doi.org/10.5152/turkarchpediatr.2025.25325, doi:10.5152/turkarchpediatr.2025.25325. This article has 0 citations.

9. (boemer2022novellossof pages 6-8): François Boemer, Claire Josse, Géraldine Luis, Emmanuel Di Valentin, Jérôme Thiry, Christophe Cello, Jean-Hubert Caberg, Caroline Dadoumont, Julie Harvengt, Aimé Lumaka, Vincent Bours, and François-Guillaume Debray. Novel loss of function variant in bckdk causes a treatable developmental and epileptic encephalopathy. International Journal of Molecular Sciences, 23:2253, Feb 2022. URL: https://doi.org/10.3390/ijms23042253, doi:10.3390/ijms23042253. This article has 14 citations.

10. (ohl2024partialsuppressionof pages 9-11): Laura Ohl, Amanda Kuhs, Ryan Pluck, Emily Durham, Michael Noji, Nathan D Philip, Zoltan Arany, and Rebecca C Ahrens-Nicklas. Partial suppression of bcaa catabolism as a potential therapy for bckdk deficiency. Molecular Genetics and Metabolism Reports, May 2024. URL: https://doi.org/10.1016/j.ymgmr.2024.101091, doi:10.1016/j.ymgmr.2024.101091. This article has 8 citations.

11. (du2022theroleof pages 6-7): Chuang Du, Wen-Jie Liu, Jing Yang, Shan-Shan Zhao, and Hui-Xin Liu. The role of branched-chain amino acids and branched-chain α-keto acid dehydrogenase kinase in metabolic disorders. Frontiers in Nutrition, Jul 2022. URL: https://doi.org/10.3389/fnut.2022.932670, doi:10.3389/fnut.2022.932670. This article has 94 citations.

12. (ohl2024partialsuppressionof pages 1-2): Laura Ohl, Amanda Kuhs, Ryan Pluck, Emily Durham, Michael Noji, Nathan D Philip, Zoltan Arany, and Rebecca C Ahrens-Nicklas. Partial suppression of bcaa catabolism as a potential therapy for bckdk deficiency. Molecular Genetics and Metabolism Reports, May 2024. URL: https://doi.org/10.1016/j.ymgmr.2024.101091, doi:10.1016/j.ymgmr.2024.101091. This article has 8 citations.

13. (bo2024primaryrolesof pages 13-15): Tomoki Bo and Junichi Fujii. Primary roles of branched chain amino acids (bcaas) and their metabolism in physiology and metabolic disorders. Molecules, 30:56, Dec 2024. URL: https://doi.org/10.3390/molecules30010056, doi:10.3390/molecules30010056. This article has 56 citations.

14. (boemer2022novellossof pages 8-10): François Boemer, Claire Josse, Géraldine Luis, Emmanuel Di Valentin, Jérôme Thiry, Christophe Cello, Jean-Hubert Caberg, Caroline Dadoumont, Julie Harvengt, Aimé Lumaka, Vincent Bours, and François-Guillaume Debray. Novel loss of function variant in bckdk causes a treatable developmental and epileptic encephalopathy. International Journal of Molecular Sciences, 23:2253, Feb 2022. URL: https://doi.org/10.3390/ijms23042253, doi:10.3390/ijms23042253. This article has 14 citations.

15. (flach2023smallmoleculebranchedchain pages 1-2): Rachel J. Roth Flach, Eliza Bollinger, Allan R. Reyes, Brigitte Laforest, Bethany L. Kormos, Shenping Liu, Matthew R. Reese, Luis A. Martinez Alsina, Leanne Buzon, Yuan Zhang, Bruce Bechle, Amy Rosado, Parag V. Sahasrabudhe, John Knafels, Samit K. Bhattacharya, Kiyoyuki Omoto, John C. Stansfield, Liam D. Hurley, LouJin Song, Lina Luo, Susanne B. Breitkopf, Mara Monetti, Teresa Cunio, Brendan Tierney, Frank J. Geoly, Jake Delmore, C. Parker Siddall, Liang Xue, Ka N. Yip, Amit S. Kalgutkar, Russell A. Miller, Bei B. Zhang, and Kevin J. Filipski. Small molecule branched-chain ketoacid dehydrogenase kinase (bdk) inhibitors with opposing effects on bdk protein levels. Nature Communications, Aug 2023. URL: https://doi.org/10.1038/s41467-023-40536-y, doi:10.1038/s41467-023-40536-y. This article has 34 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01